Tianjin Tianyao Pharmaceuticals (600488.SH): Betamethasone API Receives FDA DMF FA Letter

date
15:49 20/11/2026
avatar
GMT Eight
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that recently, the company received a DMF First Adequate Letter (DMF FA Letter) issued by the U.S. Food and Drug Administration (FDA), indicating that the FDA has completed its scientific review of the company's DMF file for betamethasone API.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it recently received a DMF First Adequate Letter (DMF FA Letter) issued by the U.S. Food and Drug Administration (FDA), indicating that the FDA has completed its scientific review of the company's DMF file for betamethasone API. Betamethasone is indicated for orthostatic hypotension caused by low-renin low-aldosterone syndrome and autonomic neuropathy, as well as allergic and autoimmune inflammatory diseases. It is currently mostly used for active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, acute leukemia, etc., and is also used in the comprehensive treatment of certain infections. The API's passing of this technical review will have a positive impact on the company's expansion into the U.S. market and improvement of its performance.